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Abstract
DNA sequence variation within human leukocyte antigen (HLA) genes mediate susceptibility to a wide range of human
diseases. The complex genetic structure of the major histocompatibility complex (MHC) makes it difficult, however, to
collect genotyping data in large cohorts. Long-range linkage disequilibrium between HLA loci and SNP markers across the
major histocompatibility complex (MHC) region offers an alternative approach through imputation to interrogate HLA
variation in existing GWAS data sets. Here we describe a computational strategy, SNP2HLA, to impute classical alleles and
amino acid polymorphisms at class I (HLA-A, -B, -C) and class II (-DPA1, -DPB1, -DQA1, -DQB1, and -DRB1) loci. To characterize
performance of SNP2HLA, we constructed two European ancestry reference panels, one based on data collected in
HapMap-CEPH pedigrees (90 individuals) and another based on data collected by the Type 1 Diabetes Genetics Consortium
(T1DGC, 5,225 individuals). We imputed HLA alleles in an independent data set from the British 1958 Birth Cohort (N= 918)
with gold standard four-digit HLA types and SNPs genotyped using the Affymetrix GeneChip 500 K and Illumina
Immunochip microarrays. We demonstrate that the sample size of the reference panel, rather than SNP density of the
genotyping platform, is critical to achieve high imputation accuracy. Using the larger T1DGC reference panel, the average
accuracy at four-digit resolution is 94.7% using the low-density Affymetrix GeneChip 500 K, and 96.7% using the high-
density Illumina Immunochip. For amino acid polymorphisms within HLA genes, we achieve 98.6% and 99.3% accuracy
using the Affymetrix GeneChip 500 K and Illumina Immunochip, respectively. Finally, we demonstrate how imputation and
association testing at amino acid resolution can facilitate fine-mapping of primary MHC association signals, giving a specific
example from type 1 diabetes.
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Introduction
The major histocompatibility complex (MHC) region on the
short arm of chromosome 6 harbors the human leukocyte antigen
(HLA) genes. The HLA genes encode cell-surface proteins that
present antigen peptides to the host immune system, and are
among the most polymorphic genes in the human genome [1].
These genes have been prominently studied because of their large
effect sizes in autoimmune diseases, infectious diseases, severe drug
reactions, and transplant medicine [2–5]. In many instances, the
observed HLA effects dwarf those of other associated variants
throughout the rest of the genome [6].
The MHC is characterized by a unique evolutionary history.
Its genetic structure is shaped not only by recombination, gene
conversion and demography but also by natural selection [7].
One of the characteristic features of the MHC is the strong
linkage disequilibrium (LD) among variants, often at considerable
distances [8]. As a result, fine-mapping genotype-phenotype
associations within the MHC to causal variants remains
challenging.
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While advances in high-throughput probe-based genotyping
technologies have enabled systematic interrogation of DNA
sequence variation through genome-wide association studies
(GWAS), they have not been effective at querying variation within
HLA genes. Probe-based methods for HLA genotyping have been
limited in resolution due to the highly polymorphic nature of these
genes. Strategies for direct typing of HLA alleles include sequence
specific oligonucleotide (SSO) hybridization, capillary (Sanger)
sequencing, and next-generation sequencing [9]. Unfortunately
these approaches do not easily scale for large cohorts since they are
labor-intensive, time-consuming and expensive.
As a potential way forward, investigators have developed
methods to infer classical HLA alleles indirectly using intragenic
SNP genotypes within the MHC. Initially, our group devised a
simple approach using selected tag SNPs that are in strong LD
with classical HLA alleles [8,10]. Subsequently, more sophisticated
approaches that model LD patterns of surrounding SNPs have
been developed to impute classical HLA alleles [11–14]. Even if
such predictions are not error-free, they are highly suitable for the
re-interpretation of existing GWAS data, because imputation
inaccuracy will generally result only in a power reduction to detect
a statistical association but not in an increased type 1 error rate. In
light of the enormous investment into GWAS in large numbers of
samples, HLA imputation is likely to add significant value to SNP
data that has already been generated [15].
An important limitation of existing HLA imputation methods,
and of many previous studies, is that they are limited to classical
HLA alleles and do not query functional coding variants within the
HLA genes. For certain traits, specific amino acid positions within
HLA molecules may play an important functional role. For
example, the role of amino acid position 57 in HLA-DQb1 for
type 1 diabetes susceptibility has been long established [16]. In
addition, our group recently identified a key role for amino acid
position 97 in HLA-B, which can account for almost all known
classical allele associations with HIV control [17].
To identify potentially causal variation within HLA genes, we
present here a method, SNP2HLA, for imputing classical HLA
alleles as well as amino acid polymorphisms in the HLA proteins
from SNP genotype data with the Beagle software package [18]
(Figure 1). In order to characterize the tradeoffs involved in HLA
imputation, we consider four scenarios covering two reference
panels (with different sample sizes) and two SNP data sets (with
different SNP densities). This study design allows us to evaluate the
impact of sample size of the reference panel and the impact of
SNP genotyping density on the imputation quality. We also assess
the accuracy of imputations at individual amino acid polymor-
phisms. Finally, we demonstrate that we can reproduce known
HLA allelic effects from genotyped SNP data in type 1 diabetes
from the publicly available Wellcome Trust Case Control
Consortium data set [19].
Results
Reference Panels for Imputation
We constructed two reference panels based on genotyping data
collected in individuals of European ancestry (Table 1). The
HapMap-CEPH panel contains 3,924 SNPs (genotyped with
Illumina GoldenGate) and 4-digit classical HLA types for HLA-A, -
B, -C, -DQA1, -DQB1 and -DRB1 for 90 unrelated individuals (180
haplotypes) [8]. The Type 1 Diabetes Genetics Consortium
(T1DGC) panel contains 5,868 SNPs (genotyped with Illumina
Immunochip) and 4-digit classical HLA types for HLA-A, -B, -C, -
DPA1, -DPB1, -DQA1, -DQB1 and -DRB1 for 5,225 unrelated
individuals (10,450 haplotypes). The T1DGC panel contains more
unique HLA alleles and amino acid polymorphisms because of its
significantly larger sample size.
Validation Panel for Benchmarking
To benchmark the HLA imputations by SNP2HLA, we used
918 individuals from the British 1958 Birth Cohort (B58BC) with
gold-standard 4-digit HLA types at HLA-A, -B, -C, -DQB1 and -
DRB1, and SNP genotype data collected on both the Affymetrix
500 K and Illumina Immunochip. The SNP genotyping density
varied widely between the data sets across the MHC region
(Figure S1 in File S1), affecting the effective number of SNPs
that could be used for imputation. For example, there were only
487 SNPs present on the Affymetrix 500 K that overlapped with
the T1DGC reference panel, in contrast with the 4,794 SNPs in
common between the Immunochip data from the B58BC
validation panel and the T1DGC reference panel (Table 2).
HLA Imputation
Using the HapMap-CEPH reference panel, we imputed in each
of the 918 B58BC individuals dosages for 70 classical 2-digit alleles
and 109 classical 4-digit alleles at HLA-A, -B, -C, -DQA1, -DQB1
and -DRB1, and 321 polymorphic amino acid positions, 915
intragenic SNPs and 42 indels (Table 1). Using the T1DGC
reference panel, we imputed 126 classical 2-digit alleles and 298
classical 4-digit alleles at HLA-A, -B, -C, -DPA1, -DPB1, -DQA1,
-DQB1 and -DRB1, and 399 polymorphic amino acid positions,
1,101 intragenic SNPs and 176 indels. (The HapMap-CEPH
panel did not contain HLA types for the HLA-DPA1 and HLA-
DPB1 loci.).
Imputation Accuracy of Classical HLA Alleles
For both reference panels, we observed that there was generally
high correlation between the imputed and typed HLA allele
frequencies (r2freq.0.99 for 2-digit and r
2
freq.0.96 for 4-digit
alleles, Figure S2 in File S1). Using the larger T1DGC panel,
SNP2HLA achieved high correlation between the imputed and
typed dosages for common HLA alleles (Figure 2). At 4-digit
resolution, we imputed 44 of 46 class I alleles and 24 of 26 class II
alleles with .1% frequency with high accuracy (r2dosage.0.8,
Table S1 in File S1). In terms of genotype concordance,
SNP2HLA achieved 81.3% and 86.5% accuracy for 4-digit HLA
alleles using Affymetrix 500 K and Illumina Immunochip,
respectively, when imputing from the HapMap-CEPH reference
panel (Table 2). This improved significantly for the larger
T1DGC panel, where SNP2HLA obtained an accuracy of 94.7%
and 96.7% using Affymetrix 500 K and Illumina Immunochip,
respectively (Table 2). Overall, these results indicate much better
performance for the T1DGC reference panel compared to the
HapMap-CEPH reference panel.
We compared these results to published benchmarking results
for HLA*IMP, a widely used software tool for imputation of
classical HLA alleles [14]. Although we did not perform a direct
head-to-head comparison with identical training and testing data
sets, both methods appear to deliver comparable imputation
accuracy at 4-digit resolution (Table S2 in File S1).
Imputation Accuracy of Amino Acid Polymorphisms
Next, we assessed the imputation quality of the polymorphic
amino acid positions by comparing imputed dosages for
individual amino acid alleles to the corresponding dosages from
the gold-standard 4-digit HLA types in the same 918 B58BC
individuals. We observed a near-perfect correlation between the
imputed and genotyped amino acid frequencies for both
HLA Imputation
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reference panels (Figure S3 in File S1). In terms of the
correlation between imputed and typed allelic dosages, we
found that 48.0% and 65.7% of amino acid positions achieved
r2dosage.0.8 using Affymetrix 500 K and Illumina Immunochip,
respectively, when imputing from the HapMap-CEPH reference
panel. Performance improved again significantly with the larger
T1DGC reference panel, where 99.2% and 99.3% of polymor-
phic amino acid positions reached r2dosage.0.8 using Affymetrix
500 K and Illumina Immunochip, respectively (Figure 3). In
terms of genotype concordance, SNP2HLA achieved 93.9% and
94.2% accuracy with the HapMap-CEPH reference panel
starting from Affymetrix 500 K and Illumina Immunochip,
respectively (Tables S3 and S4 in File S1). With the larger
T1DGC panel, this improved to 98.6% and 99.3% accuracy for
Affymetrix 500 K and Illumina Immunochip, respectively
(Tables S3 and S4 in File S1). These results demonstrate
again better performance for the larger T1DGC reference
panel, and highlight that the individual amino acid positions
can be imputed with great accuracy.
To evaluate differences in imputation performance between
HLA loci, we calculated the average dosage r2 per polymorphic
position. Starting from Illumina Immunochip data using the
T1DGC reference panel, the imputation performance was
consistently high across the class I and class II loci: HLA-A
(r2 = 0.98), HLA-B (r2 = 0.97), HLA-C (r2 = 0.96), HLA-DQB1
(r2=0.97), and HLA-DRB1 (r2=0.96), even though a limited
number of amino acid positions were more difficult to impute
(Tables S3 and S4 in File S1).
Imputation in Non-European Samples
We next assessed the imputation performance in non-European
populations. To test this, we imputed HLA alleles in three
HapMap panels (CEU/CEPH, YRI, CHB+JPT) using the
T1DGC reference panel. Using the gold-standard HLA type data
in the HapMap samples [8], 4-digit HLA imputation accuracy was
highest (98.3% over all HLA loci) in the CEU/CEPH samples, but
was considerably lower in the YRI panel (72.9%), and in the
CHB+JPT panel (86.4%) (Table 3). Strikingly, imputation
performance was quite variable across HLA loci in non-European
populations. In the CHB+JPT panel, imputation accuracy was
highest at HLA-A (98.1%) and HLA-DQB1 (96.5%), but low in
HLA-B (65.5%) and HLA-C (68.8%). In the YRI panel, imputation
performance was high in HLA-C (98.4%) and HLA-DQB1 (96.1%),
but very low at HLA-DRB1 (20.3%) and HLA-A (69.9%). These
results reinforce the need for large population-specific reference
panels in order to achieve high quality HLA imputations.
Calibration of Posterior Probabilities
Next, we evaluated how well the posterior probabilities for
imputed variants tracked with imputation accuracy. We observed
a high correlation between imputation dosage (probabilistic
representation of the number of predicted alleles) and the true
genotype dosage (0, 1, or 2), especially for imputations with high
confidence (Figure S4 in File S1). Moreover, there are more
highly confident calls (reflected by fewer imputation dosages
between 0 and 1 and between 1 and 2) for imputations derived
from the T1DGC reference panel compared to the HapMap-
Figure 1. Overview of the SNP2HLA imputation procedure. The reference panel (top) contains SNPs in the MHC, classical HLA alleles at the
class I and class II loci, and amino acid sequences corresponding to the 4-digit HLA types at each locus. For a data set with genotyped SNPs across the
MHC (bottom), we use the reference panel to impute classical alleles and their corresponding amino acid polymorphisms.
doi:10.1371/journal.pone.0064683.g001
HLA Imputation
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Table 1. Overview of the HapMap-CEPH and T1DGC reference panels and the B58BC validation panel.
Reference panel Validation panel
Sample set HapMap-CEPH Type 1 Diabetes Genetics
Consortium (T1DGC)
British 1958 Birth Cohort (B58BC)
Sample size 90 5,225 918
Genotyping platform Illumina GoldenGate Illumina Immunochip Affymetrix 500 K Illumina Immunochip
Number of SNPs in MHC 4,791 7,135 916 7,563
Number of SNPs passing QC 3,924 5,868 890 5,893
Number of 4-digit classical HLA alleles
HLA-A 17 50 25
HLA-B 29 97 40
HLA-C 19 33 20
HLA-DPA1 – 7 –
HLA-DPB1 – 34 –
HLA-DQA1 7 8 –
HLA-DQB1 14 18 17
HLA-DRB1 23 51 34
Number of polymorphic positions
Intragenic SNPs 915 1,101 858
Amino acids 321 399 289
Indels 42 176 37
Total number of biallelic markers 5,986 8,961 5,112
The MHC region is defined here as 29–34 Mb on chr6 (hg17). Sample size is based on unrelated (founder) individuals. The number of unique 4-digit classical HLA alleles
at each locus is shown for each data set. Intragenic SNPs, amino acids, and indels represent unique polymorphic positions as defined by the classical HLA types in each
data set.
doi:10.1371/journal.pone.0064683.t001
Table 2. Imputation accuracy measured as the genotype concordance for two- and four-digit classical HLA alleles measured in the
British 1958 Birth Cohort (B58BC, 918 individuals) as a function of reference panel (HapMap or T1DGC) and genotyping platform (in
B58BC).
HapMap reference panel T1DGC reference panel
Genotyping platform Affymetrix 500 K Illumina Immunochip Affymetrix 500 K Illumina Immunochip
Genotyped SNPs 916 7563 916 7563
Overlapping SNPs 332 2466 487 4794
4-digit resolution accuracy
HLA-A 89.9% 95.4% 97.2% 98.1%
HLA-B 83.0% 88.2% 94.7% 96.8%
HLA-C 87.2% 90.7% 96.1% 96.9%
HLA-DQB1 72.3% 71.8% 95.5% 98.3%
HLA-DRB1 72.6% 84.3% 89.3% 93.3%
All loci 81.3% 86.5% 94.7% 96.7%
2-digit resolution accuracy
HLA-A 89.9% 95.1% 98.4% 98.7%
HLA-B 83.0% 90.1% 96.1% 98.2%
HLA-C 87.6% 90.9% 96.8% 97.2%
HLA-DQB1 80.2% 78.0% 97.7% 99.2%
HLA-DRB1 82.4% 91.0% 95.6% 98.5%
All loci 84.6% 89.0% 96.9% 98.4%
Comparisons were made only if both alleles were typed at the same resolution (two- or four-digit). Accuracy was based on the same set of variants, allowing a direct and
fair comparison between reference panels and genotyping platforms.
doi:10.1371/journal.pone.0064683.t002
HLA Imputation
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CEPH panel. These results suggest that probabilistic dosages
correlate better with true genotypes than best-guess genotypes, and
should be taken into account for subsequent statistical analyses and
association testing.
HLA Imputation in WTCCC Type 1 Diabetes
Lastly, we wanted to evaluate the potential for SNP2HLA to
reproduce HLA associations from a GWAS dataset. To this end,
we used the WTCCC type 1 diabetes cases and controls [19]. The
cases consist of 1,963 individuals and the controls consist of 2,939
individuals, all genotyped with the Affymetrix 500 K array. The
controls include the same 918 individuals from the B58BC panel
that were used for the imputation benchmark above. After quality
control, 511 SNPs remained that overlapped with the T1DGC
reference panel.
We applied SNP2HLA to impute all markers, and then tested
them for association. Among all of these markers, the top signal
was HLA-DQb1 amino acid position 57 (P,102280) (Figure 4).
This highly significant amino acid position is historically well
known as a potential causal risk factor for type 1 diabetes [16].
This demonstrates that the value of SNP2HLA to leverage large
GWAS data sets to impute individual amino acids and to pinpoint
the location of potentially causal amino acid sites.
We also performed haplotype analysis in this dataset to test if
the haplotype effect sizes are concordant with the literature. We
specifically calculated the risk estimates for haplotypes of classical
Figure 2. Correlation between imputed and typed dosages (r2dosage) of classical HLA alleles in the B58BC as a function of typed
allele frequency for imputation from the (a) Affymetrix 500 K or (b) Illumina Immunochip platform using the HapMap-CEPH
reference panel, and imputation from the (c) Affymetrix 500 K or (d) Illumina Immunochip platform using the T1DGC reference
panel. Black points indicate 2-digit HLA alleles. Red points indicate 4-digit HLA alleles.
doi:10.1371/journal.pone.0064683.g002
HLA Imputation
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alleles spanning HLA-DRB1, HLA-DQA1 and HLA-DQB1, as these
have been estimated by others [20]. Although the previously
reported effects were odds ratios based on transmission/non-
transmission of alleles (ORT) from familial data, we expect that
the estimated odds ratios in the WTCCC case-control data will be
concordant as long as the imputations and phasing are accurate.
Indeed, our results show that the haplotype effect sizes are highly
concordant within the range of sampling error between two
different datasets (Figure 5 and Table S5 in File S1). The
haplotypes that are known as ‘‘high risk’’ confer high risk in our
analysis, and haplotypes known as ‘‘low risk’’ confer similarly low
risk. These empirical results demonstrate the validity of our
imputations and the inferred HLA haplotypes.
Discussion
We have developed a method, SNP2HLA, to impute HLA
amino acids and classical HLA alleles using SNP genotype data
within the MHC region. With a large reference panel we have
demonstrated that our approach can yield high-quality imputa-
tions of classical HLA alleles and coding variation within the HLA
genes. Even with relatively modest SNP genotyping coverage (for
example, first-generation GWAS arrays), the long-range LD
patterns in the region make it possible to accurately impute
HLA variants.
The imputation quality of SNP2HLA is determined primarily
by the size and quality of the reference panel rather than the SNP
Figure 3. Correlation between imputed and typed dosages (r2dosage) of polymorphic amino acids in the B58BC as a function of
typed allele frequency for imputation from the (a) Affymetrix 500 K or (b) Illumina Immunochip platform using the HapMap-CEPH
reference panel, and imputation from the (c) Affymetrix 500 K or (d) Illumina Immunochip platform using the T1DGC reference
panel. Black points indicate bi-allelic positions. Red points indicate poly-allelic positions.
doi:10.1371/journal.pone.0064683.g003
HLA Imputation
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e64683
genotyping density. Accuracy is generally lower for low-frequency
or rare alleles, which is similar to experience with imputation
methods outside of the MHC region [21]. This limitation may be
mitigated by using larger reference panels containing multiple
observations (that is, haplotypes) of low-frequency alleles. As a
result, application of SNP2HLA with a large T1DGC reference
panel with .10,000 haplotypes achieved high imputation
accuracy for both classical HLA alleles and amino acids. We
could not assess performance at HLA-DPA1, HLA-DPB1, and
HLA-DQA1, since these genes were not available to us for
evaluation. Because HLA-B and HLA-DRB1 are the most
polymorphic genes in class I and II (and therefore considered
the most difficult to impute), our results may be slightly
conservative with respect to HLA-DQA1, -DPA1 and -DPB1.
The density of SNPs typed within the MHC has a modest but
measureable effect on HLA imputation quality. The Immunochip,
which has between 2,500 and 5,000 overlapping SNPs with both
HapMap and T1DGC reference panels, consistently showed
higher imputation accuracy compared to the Affymetrix 500 K
array, which only shares 300–400 SNPs with these reference
panels. This effect is most prominent at the class II locus HLA-
DRB1, where Immunochip showed an average improvement of
6% in four-digit HLA accuracy over the 500 K array, compared to
Table 3. Imputation accuracy of classical alleles at 4-digit
resolution across worldwide populations.
CEU/CEPH YRI CHB+JPT
HLA-A 99.1% 69.9% 98.1%
HLA-B 96.8% 90.5% 65.6%
HLA-C 99.1% 98.4% 68.8%
HLA-DQA1 98.5% 64.9% 96.3%
HLA-DQB1 99.1% 96.1% 96.5%
HLA-DRB1 96.9% 20.3% 92.3%
All loci 98.3% 72.9% 86.4%
Imputations were performed using the T1DGC reference panel, and accuracy
(as measured by genotype concordance) in the three HapMap panels (CEU/
CEPH, YRI and CHB+JPT) with the publicly available gold-standard HLA
genotype data [8]. Accuracy is consistently high across all loci in Europeans
(CEU/CEPH), but much worse in the African (YRI) and East-Asian (CHB+JPT)
populations.
doi:10.1371/journal.pone.0064683.t003
Figure 4. Association analysis of WTCCC type 1 diabetes data. We imputed classical HLA alleles and polymorphic amino acids in 1,963 cases
and 2,939 controls using the T1DGC reference panel, and tested all variants for association with logistic regression. Of all variants tested, the top hit
maps to amino acid position 57 in HLA-DQb1, consistent with a previous study [16].
doi:10.1371/journal.pone.0064683.g004
Figure 5. Haplotype risk analysis of WTCCC type 1 diabetes
data. We assessed the risk of haplotypes spanning HLA-DRB1, HLA-
DQA1 and HLA-DQB1, and compared these to the published risk
estimates from an independent study [20]. The published odds ratios
were based on transmission/non-transmission of alleles from familial
data, while our odds ratios were estimated from case/control data. We
used the same classification scheme by dividing haplotypes into three
risk groups. The odds ratios are computed with respect to the DRB1*01-
DQA1*0101-DQB1*0501 haplotype.
doi:10.1371/journal.pone.0064683.g005
HLA Imputation
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an average improvement of 0.9% at class I loci. This may be due
to the relatively shorter spans of linkage disequilibrium within the
class II region compared to class I, rendering individual distal
SNPs within the class II region somewhat less informative about
the haplotypes.
The power of our approach is not only in highly accurate
imputation of HLA classical alleles, but also in allowing individual
amino acid polymorphisms to be tested. This gives users the ability
to query variation within HLA genes for association in an entirely
different way than previously applied. We demonstrated the
potency of this approach using the WTCCC type 1 diabetes data
[19]. By simultaneously testing HLA alleles, amino acids, and
SNPs, we were able to pinpoint the HLA-DQb1 position 57 as the
top signal, which is recognized as the major risk factor for type 1
diabetes [16]. Another strength of SNP2HLA is that phased
haplotypes are obtained. Using the WTCCC type 1 diabetes data,
we were able to accurately assess the risk of haplotypes spanning
HLA-DRB1, HLA-DQA1 and HLA-DQB1. Our estimates of effect
sizes were consistent with published effect sizes.
One limitation of our imputation method (and of all other
imputation methods) is that the reference panel should properly
represent the target population. We observed that imputation
quality is inconsistent when imputing HLA variants in a non-
European population using a predominantly European reference
panel. Currently, we are not aware of a large data set with SNP
and high-resolution HLA types in non-European populations, and
argue that resources should be made available to generate
multiethnic panels to enable HLA imputation in worldwide
populations, including admixed populations. In constructing
additional reference panels, each investigator will have to weigh
the benefits of imputing rare alleles with greater accuracy against
the additional resources required to expand the sample size of the
reference panel.
There are other limitations of our method. First, there are
known limitations to established methods for HLA typing [22]. As
a result, there may be errors in the reference panel that may limit
imputation accuracy, and errors in the gold standard that limit the
evaluation of accuracy. Without commenting on the intrinsic error
rate of classical HLA typing itself, our results show that LD-based
imputation can achieve high quality using a large reference panel.
Second, while this method enables interrogation of polymorphisms
at the widely studied HLA loci, it does not capture variation at
hundreds of other genes present in the MHC [23–25]. In many
instances, variation at these genes is captured by SNPs throughout
the MHC, but comprehensive interrogation of the entire region
will ultimately require high-throughput sequencing, making
imputation redundant.
The immense volume of data generated from recent GWAS
provides an excellent opportunity to apply imputation techniques
to fine-map MHC associations to classical alleles and amino acids
of the HLA loci. We and others have previously demonstrated the
potential of HLA imputation for a wide range of phenotypes
including host control of HIV-1 replication [17,26], rheumatoid
arthritis [27], ulcerative colitis [28], primary biliary cirrhosis [29],
psoriasis [30], ankylosing spondylitis [31], multiple sclerosis [32],
liver carcinoma [33], Hodgkin lymphoma [34], carbamazepine-
induced hypersensitivity [35], and myasthenia gravis [36]. For
autoimmune or inflammatory diseases, the identification of
classical allele associations or the fine-mapping of specific amino
acid positions may facilitate the evaluation of specific peptides as
antigens through binding assays and molecular modeling. For
drug-induced hypersensitivity, a molecular model has recently
been proposed that might explain how specific drug binding to the
HLA pocket can perturb the T cell repertoire in an individual and
cause T-cell mediated hypersensitivity [5]. Regardless of the
underlying biology, we believe that imputation approaches for the
MHC can add significant value to already existing data sets.
Materials and Methods
Reference Data
We constructed the HapMap-CEPH reference panel with
MHC genotype data as described previously consisting of 182
individuals (29 extended families containing 45 unrelated parent-
offspring trios) of European ancestry from the Centre d’Etude du
Polymorphisme Humain (CEPH) collection [8]. Genotype data
included 4,791 SNPs within the MHC region (chr6: 29–34 Mb)
assayed using the Illumina GoldenGate platform and classical
types for HLA-A, -B, -C, -DQA1, -DQB1, and -DRB1 at four-digit
resolution. We corrected a small number of HLA typing errors in
these samples using next-generation 454 sequencing at the class I
loci [22]. Of the CEPH individuals, we kept only founder
individuals on the basis of the known familial relationships.
We constructed the T1DGC reference panel based on data
collected in 5,225 unrelated individuals by the Type 1 Diabetes
Genetics Consortium (T1DGC). Genotype data included 7,135
SNPs within the MHC region assayed with the Illumina
Immunochip platform, and classical types for HLA-A, -B, -C, -
DQA1, -DQB1, -DPA1, -DPB1 and -DRB1 at four-digit resolution.
For both reference panels, we used the software package PLINK
[37] to remove SNPs with low minor allele frequency (,1%), high
proportion of missing genotypes (.5% across individuals), and out
of Hardy-Weinberg equilibrium (P,1026). We used the KING
software to test for relatedness between all individuals using the
genome-wide Immunochip data, and kept only unrelated individ-
uals [38]. We also performed principal components analysis on the
same data, and confirmed that the overwhelming majority of the
T1DGC individuals are of European ancestry (as judged by
overlap with European ancestry reference populations from
HapMap). The T1DGC reference panel can be obtained from
the NIDDK repository at https://www.niddkrepository.org/
niddk/home.do.
A key step in our approach is to impute not only classical HLA
alleles but also amino acid polymorphisms and SNPs. First, we
defined binary markers that correspond to the presence and
absence of each unique 2- and 4-digit HLA allele. Second, we
extracted the unique DNA and amino acid sequences for all
observed HLA alleles from the EMBL-EBI Immunogenetics HLA
Database [39] (http://www.ebi.ac.uk/imgt/hla/), and encoded
polymorphic nucleotide and amino acid positions as binary
markers in the reference panel. For a multi-allelic position, we
added a binary marker for each allele. For example, if one amino
acid position has three different alleles, we encoded the position
using three binary markers each corresponding to the presence
and absence of each allele. We also encoded separately insertions,
deletions or truncations using binary markers. The purpose of
converting all genetic variations into binary markers is to provide a
basic unit that can be flexibly tested in the downstream association
analysis. We removed markers (HLA alleles, amino acid positions,
etc.) with very low allele frequency (,0.01%). We used Beagle [18]
to phase genotype data into individual haplotypes, taking into
account familial relationships wherever available. The procedure
for generating a phased reference panel is fully implemented in our
software and made available. Overall, the HapMap-CEPH panel
comprises 180 haplotypes and the T1DGC panel 10,450
haplotypes.
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Imputation of Classical HLA Alleles and Amino Acids
Given SNP data of sample individuals, we imputed HLA
types using the HapMap or T1DGC extended reference panel.
First, we extracted SNPs located within the MHC region (chr6:
29–34 Mb on build 36/hg18), removed SNPs with minor allele
frequency ,2.5%, and checked the data to ensure that each
SNP is oriented on the same strand as the reference panel. We
used Beagle to impute all missing SNPs, classical HLA alleles,
and amino acid polymorphisms using default parameters (10
iterations of phasing/imputation, testing 4 pairs of haplotype
pairs for each individual at each iteration), but allowing a larger
window size (maxwindow=2000) for the Illumina Immunochip
than for the Affymetrix 500 K chip (maxwindow=1000). The
output includes posterior probabilities and allelic dosages for
each imputed variant, best-guess genotypes and phased haplo-
types for each individual.
Evaluation of Imputation Performance
To validate our imputation method, we utilized genotype data
in 918 individuals from the British 1958 Birth Cohort [40]. These
individuals have primarily Northern and Western European
ancestry, as confirmed by principal components analysis in the
WTCCC data [19]. Data for the British 1958 Birth Cohort were
obtained from the European Genome-phenome Archive (EGA) at
https://www.ebi.ac.uk/ega/. These individuals were genotyped
using the Affymetrix GeneChip 500 K platform (with 916 SNPs in
the MHC) and the Illumina Immunochip platform (with 7,563
SNPs in the MHC). In addition, these same subjects have gold-
standard 4-digit HLA genotypes (at HLA-A, HLA-B, HLA-C, HLA-
DRB1 and HLA-DQB1) generated by the Juvenile Diabetes
Research Foundation/Wellcome Trust Diabetes and Inflamma-
tion Laboratory.
For each imputation scenario, we calculated the imputation
accuracy at each HLA locus by summing across all individuals the
dosage of each true HLA allele in the individual, and divided by
the total number of observation (i.e. number of chromosomes).
Acc(L)~
Pn
i~1
Di(A1i,L)zDi(A2i,L)
2n
where Acc(L) represents the imputation accuracy at HLA locus L,
where L might be a classical HLA locus (e.g. DRB1) or an
individual polymorphic nucleotide or amino acid site. The
parameter n denotes the number of individuals, Di represents the
imputed dosage of an allele in individual i, and alleles A1i,L and
A2i,L represent the true (gold standard) HLA types for individual i
at locus L. If the individual was homozygous for a single allele
(defined by A1), we only included the A1 term in the calculation.
This scheme allows uncertain but partially correct imputations to
contribute to the overall accuracy.
To evaluate imputation performance in individual HLA alleles
and amino acids, we calculated the r2 correlation between imputed
and typed dosages for all HLA variants (encoded as bi-allelic
markers). For amino acid positions with two alleles, we used the
Pearson product moment correlation coefficient for two variables x
and y, which denote the imputed and typed dosages respectively in
n individuals.
r2~
P
xiyi{
P
xið Þ
P
yið Þ
n
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P
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P
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n
 ! P
yi2{
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n
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For amino acid positions with more than two alleles, we used a
variation of the Pearson r2 formula to determine the R2 correlation
between vectors of imputed and typed dosages, where each vector
contains the dosages for different amino acid alleles at a specific
position.
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where Xi represents the vector of imputed dosages for amino acids
at a single position for individual i, and Yi represents the vector of
typed dosages for amino acids at a single position for individual i
across n individuals in the independent data set.
Association Testing
We obtained the WTCCC genotype-phenotype data from the
European Genotype Archive (http://www.ebi.ac.uk/ega), and
imputed classical alleles and amino acids using the T1DGC
reference panel. After imputation, we checked that the
cumulative dosage of classical alleles of a given HLA locus
summed to ,2 for each individual. We used logistic regression
modeling to test the allelic dosages of all imputed variants
encoded by the T1DGC reference panel for association to
disease status. By simultaneously testing all markers including
HLA alleles, amino acids, and SNPs, we aim to avoid possible
bias in the interpretation that can happen if we only examine
one type of marker such as HLA alleles, since it is generally
unknown a priori which variations are driving the association. To
test individual amino acid positions, we test a model with all
amino acid alleles of a given position, fitting individual effects
for each of the alleles. The statistical significance is evaluated by
calculating the deviance (22 6 log likelihood) of the alternative
model compared to the null model.
Obtaining SNP2HLA
Instructions for obtaining SNP2HLA and the HapMap and
T1DGC reference panels can be found at http://www.
broadinstitute.org/mpg/snp2hla/. Beagle should be obtained
separately from the web site http://faculty.washington.edu/
browning/beagle/beagle.html.
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